IR CD-LD
Total Payments
$4.1M
Transactions
454
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.6M | 291 | 0 |
| 2019 | $1.5M | 163 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.1M | 454 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS | Amneal Pharmaceuticals LLC | $2.6M | 0 |
| A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations | Amneal Pharmaceuticals LLC | $1.5M | 0 |
Top Doctors Receiving Payments for IR CD-LD
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Albany, NY | $4.1M | 454 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.1M
- Total Doctors 0
- Transactions 454
About IR CD-LD
IR CD-LD is a drug associated with $4.1M in payments to 0 healthcare providers, recorded across 454 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2019 to 2020. In 2020, $2.6M was paid across 291 transactions to 0 doctors.
The most common payment nature for IR CD-LD is "Unspecified" ($4.1M, 100.0% of total).
IR CD-LD is associated with 2 research studies, including "A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS" ($2.6M).